Category: News

The AACR Project GENIE Data Model, recently released by the AACR GENIE consortium, is an open-access tool designed to help simplify data harmonization in precision oncology. Learn more about the development of the model, how it can help cancer researchers, and future plans for its expansion

The post Harmonizing Data Collection for Precision Oncology: AACR Project GENIE® Data Model appeared first on American Association for Cancer Research (AACR).

Cancer Research Catalyst has launched a new monthly series, “Unboxing Cancer News,” that highlights exciting cancer research discoveries. Read the first installment and learn about transmissible cancer in catfish, federal- vs. industry-sponsored trials, symptoms that may predict early-onset colorectal cancer, and engineered yeast that produce ingredients to make chemotherapy drugs.

The post Unboxing Cancer News, August 2026: Fishy Cancer, Federal- vs. Industry-funded Trials, and More   appeared first on American Association for Cancer Research (AACR).

Today, the U.S. Food and Drug Administration approved daraxonrasib (Rasonque), a groundbreaking new drug for pancreatic cancer that targets the RAS family of proteins. Catch up on the amazing progress scientists have made in targeting RAS by reading the AACR blog’s extensive coverage of the field, from the discovery of RAS as an oncogene to the development of drugs targeting this once-elusive protein and the new advances on the horizon.

The post Breaking News: Daraxonrasib Approved for Pancreatic Cancer appeared first on American Association for Cancer Research (AACR).

Featuring insights from Carl H. June, MD, FAACR, this post covers the ongoing challenges facing CAR T-cell therapy and some of the latest approaches that strive to overcome these hurdles. Learn about recent efforts to prevent T-cell exhaustion, infiltrate the tumor microenvironment of solid tumors, shorten the manufacturing time, and more.

The post Driving CAR T-cell Therapy in New Directions appeared first on American Association for Cancer Research (AACR).

The August 2026 Editors’ Picks from AACR journals cover the impact of weight loss and omega-3 supplementation on breast cancer risk, early-onset cancer prediction, and more.

The post Editors’ Picks, August 2026: Weight Loss and Breast Cancer Biomarkers, Predicting Early-onset Cancer Cases, and More appeared first on American Association for Cancer Research (AACR).

Ovarian cancer is often diagnosed at an advanced stage, but research is reshaping how scientists understand and treat the disease. From discoveries about its origins to new FDA-approved therapies, learn how scientific advances are creating new possibilities for patients, including the first immunotherapy-based regimen for this cancer type and a first-of-its-kind selective glucocorticoid receptor antagonist.

The post How New Science is Reshaping Ovarian Cancer Treatment and Care appeared first on American Association for Cancer Research (AACR).

Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New research has helped to revolutionize the drug class and deliver next-generation designs and approaches.

The post Smart Chemotherapy Gets Smarter: Advances in Antibody-drug Conjugates appeared first on American Association for Cancer Research (AACR).

A variety of national and local news outlets have highlighted AACR initiatives and experts in recent weeks. Learn about the news stories covering the findings from the AACR Cancer Disparities Progress Report 2026 and AACR’s statement about the White House Office of Management and Budget’s proposal to change how federal grants are awarded and managed.

The post AACR in the News: Cancer Disparities Progress Report and OMB Statement appeared first on American Association for Cancer Research (AACR).

Antibody-drug conjugates, or ADCs, are increasingly common cancer therapies. But what are they? How do they work? And how were they discovered? Learn about the history of ADCs, their functions, the ADCs currently approved by the FDA, and more.

The post What Are Antibody-drug Conjugates? appeared first on American Association for Cancer Research (AACR).

We highlight some of the many innovations showcased at the inaugural AACR Drug Discovery and Development (AACR D3) conference, including investigational KRAS degraders, approaches to drug p53 and MYC, and new AI tools for drug discovery.

The post AACR D3 Offered a Peek Into the Cancer Drug Pipeline, Innovative AI Tools, and More appeared first on American Association for Cancer Research (AACR).